Request Trial

Marisa Woutersen

Key details

Marisa Woutersen is a senior reporter for Life Sciences Intellectual Property Review and World IP Review. She largely covers intellectual property developments across the global life sciences sector, including pharmaceuticals, biotechnology, medtech, AI, M&A and regulation.

Since joining Newton Media in 2023, Marisa has reported across a wide range of topics, from the rise of generative AI and its impact on the creative industries to the crossover between intellectual property and sport, including issues affecting athletes, as well as global pharmaceutical disputes, vaccine technology, access to medicines and life sciences M&A.

She has reported live from court and regularly travels to international conferences, where she interviews lawyers, business leaders and other key industry figures.

Marisa holds a Master’s in International Law and a BA in Politics and International Relations from the University of Sussex, and is currently completing her NCTJ Diploma in Journalism.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 456

Articles by Marisa Woutersen

LSPN: Counsel grapple with AI’s impact on training and critical thinking
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
Legal heads from Pfizer and The Broad Institute stress the need for cross-disciplinary teams and careful training as AI software becomes mainstream, reports Marisa Woutersen from LSPN 2025.   8 May 2025
LSPN: Trump's policy storm causing chaos and confusion
Americas
LSPN: Trump's policy storm causing chaos and confusion
In just 100 days, the Trump administration has issued a record-breaking 90 executive orders—triggering operational uncertainty, staffing upheaval, and growing delays at the US Patent and Trademark Office, hears Marisa Woutersen at LSPN in Boston.   7 May 2025
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
The ‘Wands factors’ are extending patent litigation—allowing functionally defined claims to survive longer than expected, hears Marisa Woutersen in Boston.   6 May 2025
Americas
Foley adds five-partner team from Perkins Coie and K&L Gates
The team brings experience in Section 337 investigations, post-grant proceedings, and complex patent litigation in biopharmaceutical and medical device sectors.   6 May 2025
Europe
UPC orders 17-country ban on EOFlow's pumps in Insulet feud
Appeals court overturns lower court ruling in decision establishing key standards for patent interpretation | Global dispute between the two insulin pump makers intensifies amid separate US trade secret litigation.   2 May 2025
Americas
US warns of rising counterfeit drug threat from India and China
Latest report highlights increasing concerns over counterfeit pharmaceuticals, IP barriers, and market access challenges | Key countries to watch include India, China, the UAE, and Singapore | Report also outlines challenges in Mexico, Russia, Brazil, and Indonesia.   1 May 2025
Americas
How pharma should prep for the six-bill avalanche from Congress
The bipartisan legislative push could create big hurdles for drug development, with concerns mounting over limited patent protections and increased litigation risks, hears Marisa Woutersen.   17 April 2025
Careers
Lathrop GPM adds portfolio management specialist
New partner brings 16 years of experience in biotechnology and pharmaceutical patent prosecution to Chicago | Regularly advises on animal biotechnology, antibodies and biologics, cell biology, chemical technologies, medical devices, and vaccines.   16 April 2025
Americas
Novo Nordisk, Bayer, GSK among giants accused in drug delivery suits
Texas company launches sweeping lawsuits against five major players, alleging infringement of medical device patents tied to legacy Sanofi-Aventis technologies | Cases put billions in revenue and key drug delivery products in the spotlight.   14 April 2025
Americas
BMS notches legal win and FDA nod
Pharma giant dodges threat as US judge dismisses monopoly claims over its blockbuster cancer drug | FDA approves new treatment combo for advanced colorectal cancer.   10 April 2025

Not finding what you're looking for, please try resetting your applied search and filters,
or try the full site search.